PharmaMar
Pre-Approval PRO BETAStale Activity
No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 9/21/2023
Pipeline by Phase
Therapeutic Focus
Clinical Trials (38)
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Started: 9/21/2023
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Started: 7/22/2022
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Started: 6/4/2021
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Started: 8/30/2016
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Started: 6/1/2010
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Started: 5/1/2015
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
Started: 4/19/2023
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Started: 8/25/2015
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
Started: 12/1/2010
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Started: 8/1/2009
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Started: 1/16/2018
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Started: 5/8/2017
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Started: 10/25/2016
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Started: 7/1/2010
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Started: 6/13/2012
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Started: 8/12/2015
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
Started: 9/11/2013
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Started: 4/28/2023
PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Started: 12/23/2022
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Started: 9/6/2017
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Started: 1/14/2021
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Started: 10/7/2020
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Started: 5/6/2016
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
Started: 1/25/2022
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
Started: 5/12/2020
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Started: 12/12/2014
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Started: 6/1/2014
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Started: 9/1/2013
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Started: 5/25/2011
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Started: 7/30/2014
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Started: 4/1/2013
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Started: 11/1/2011
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Started: 5/1/2011
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Started: 3/1/2009
Study of PM060184 in Patients With Advanced Solid Tumors
Started: 1/1/2011
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
Started: 5/1/2011
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Started: 1/1/2009
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Started: 12/1/2008